Insulet Corporation (PODD) Financial Statements
Historical financial data — 42 statements covering FY2016–FY2025
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposa...
Insulet Corporation's revenue increased 30.7% year over year, from $2.07B to $2.71B.
Net income decreased 40.9% over the same period, from $418.3M to $247.1M.
Over the 9-year period from FY2016 to FY2025, revenue grew by 638% in total.
Total debt decreased by 28.2% to $930.8M.
The debt-to-equity ratio stands at 0.61, indicating a moderate leverage profile.
Operating cash flow grew 32.3% to $569.3M.
Insulet Corporation maintains a moderate net profit margin of 9.1%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2024 | $543.9M+11.3% | $77.5M | $377.1M | $88.1M | $98.5M | $3.03B | $1.36B | $1.12B |
| Q4 FY2024 | $597.5M+9.9% | $100.7M | $430.9M | $109.3M | $147.7M | $3.09B | $1.30B | $1.21B |
| Q1 FY2025 | $569.0M-4.8% | $35.4M | $409.0M | $88.8M | $63.8M | $3.52B | $1.61B | $1.33B |
| Q2 FY2025 | $649.1M+14.1% | $22.5M | $452.3M | $121.1M | $196.5M | $3.47B | $939.0M | $1.46B |
| Q3 FY2025 | $706.2M+8.8% | $87.6M | $510.0M | $117.6M | $125.7M | $3.03B | $934.9M | $1.38B |
| Q4 FY2025 | $783.8M+11.0% | $101.6M | $568.6M | $146.3M | $183.3M | $3.19B | $930.8M | $1.52B |
| Q1 FY2026 | $761.7M-2.8% | $91.1M | $529.1M | $122.1M | $113.8M | $2.99B | $1.01B | $1.30B |
| Q2 FY2026 | $801.7M+5.3% | $95.0M | $562.5M | $129.7M | $88.4M | $3.17B | $948.4M | $1.42B |
Balance Sheet Summary (Q2 FY2026)
Insulet Corporation (PODD) Financial Statements & Revenue History
Insulet Corporation (PODD) is a US-listed stock operating in the Healthcare sector, specifically the Surgical & Medical Instruments & Apparatus industry trading at $140.96 with a market capitalization of $10. This page provides 42 historical financial statements for Insulet Corporation, including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, Insulet Corporation reported revenue of $2.7 billion, representing 30.7% year-over-year growth. The net profit margin of 9.1% indicates moderate profitability. The debt-to-equity ratio of 0.61 reflects moderate leverage.
PODD Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows Insulet Corporation's revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether PODD is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track PODD's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently Insulet Corporation converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of PODD's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use PODD Financial Data
Investors use Insulet Corporation's financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare PODD's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how PODD's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View PODD's financial health score, earnings, and pre-market pricing.
Financial data is sourced from Insulet Corporation's SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.PODD trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.